FDA Panel Gives Unanimous ‘No’ to Y-mAbs Biologic for Pediatric Neuroblastoma

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 16-0 on Friday against recommending Y-mAbs Therapeutics’ biologic candidate for the treatment of central nervous system/leptomeningeal (CNS/LM) metastases in children with neuroblastoma who have had the standard treatment for CNS disease.
Source: Drug Industry Daily